Kennedy Capital Management, Inc. Neurocrine Biosciences Inc Transaction History

Kennedy Capital Management, Inc.

$4.35 Billion
Q2 2024

A detailed history of Kennedy Capital Management, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Kennedy Capital Management, Inc. holds 28,480 shares of NBIX stock, worth $3.57 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

28,480

Previous 33,236 14.31%

Holding current value

$3.57 Million

Previous $4.58 Million 14.47%

% of portfolio

0.09%

Previous 0.1%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$130.86 - $143.19 $622,370 - $681,011	-4,756 Reduced 14.31%	28,480 $3.92 Million
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $1.55 Million - $1.7 Million	11,850 Added 55.41%	33,236 $4.58 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $3.2 Million - $4.01 Million	-30,185 Reduced 58.53%	21,386 $2.82 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $478,937 - $596,507	-5,094 Reduced 8.99%	51,571 $5.8 Million
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $898,164 - $1.05 Million	10,032 Added 21.51%	56,665 $5.34 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $2.23 Million - $2.91 Million	23,673 Added 103.11%	46,633 $4.72 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $98,716 - $117,530	-925 Reduced 3.87%	22,960 $2.74 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $1.83 Million - $2.15 Million	19,899 Added 499.22%	23,885 $2.54 Million
Q2 2022 Aug 10, 2022	BUY	$75.79 - $100.07 $302,098 - $398,879	3,986 New	3,986 $389,000

Others Institutions Holding NBIX

# of Institutions

629

Shares Held

94.2M

Call Options Held

692K

Put Options Held

406K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Kennedy Capital Management, Inc. with notifications on news.

Account

Kennedy Capital Management, Inc. Neurocrine Biosciences Inc Transaction History